WO1991015498A3 - Derives nucleosidiques - Google Patents

Derives nucleosidiques Download PDF

Info

Publication number
WO1991015498A3
WO1991015498A3 PCT/EP1991/000639 EP9100639W WO9115498A3 WO 1991015498 A3 WO1991015498 A3 WO 1991015498A3 EP 9100639 W EP9100639 W EP 9100639W WO 9115498 A3 WO9115498 A3 WO 9115498A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
nucleoside derivatives
compounds
purine
acyl
Prior art date
Application number
PCT/EP1991/000639
Other languages
English (en)
Other versions
WO1991015498A2 (fr
Inventor
Jo Klaveness
Kjell Undheim
Original Assignee
Holmes Michael John
Nycomed As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991015498(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909007566A external-priority patent/GB9007566D0/en
Priority claimed from GB909007650A external-priority patent/GB9007650D0/en
Priority claimed from GB909007651A external-priority patent/GB9007651D0/en
Application filed by Holmes Michael John, Nycomed As filed Critical Holmes Michael John
Priority to JP91506841A priority Critical patent/JPH05505815A/ja
Priority to CA002079796A priority patent/CA2079796A1/fr
Publication of WO1991015498A2 publication Critical patent/WO1991015498A2/fr
Publication of WO1991015498A3 publication Critical patent/WO1991015498A3/fr
Priority to NO92923849A priority patent/NO923849L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

Composés nucléosidiques répondant à la formule (I): Y1O-G-X dans laquelle Y1 est un atome d'hydrogène ou un groupe acyle ou acyloxyméthyle; G est le résidu de la moitié glycone du nucléoside; et X est une base de purine ou de pyrimidine ou un dérivé ester, amide ou acyloxyalkyle de cette base. Les composés présentent une activité antivirale.
PCT/EP1991/000639 1990-04-04 1991-04-04 Derives nucleosidiques WO1991015498A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP91506841A JPH05505815A (ja) 1990-04-04 1991-04-04 ヌクレオシド誘導体
CA002079796A CA2079796A1 (fr) 1990-04-04 1991-04-04 Derives de nucleosides
NO92923849A NO923849L (no) 1990-04-04 1992-10-02 Nukleosid-derivater

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9007650.6 1990-04-04
GB909007566A GB9007566D0 (en) 1990-04-04 1990-04-04 Nucleoside derivatives
GB9007566.4 1990-04-04
GB909007650A GB9007650D0 (en) 1990-04-04 1990-04-04 Nucleoside derivatives
GB909007651A GB9007651D0 (en) 1990-04-04 1990-04-04 Nucleoside derivatives
GB9007651.4 1990-04-04

Publications (2)

Publication Number Publication Date
WO1991015498A2 WO1991015498A2 (fr) 1991-10-17
WO1991015498A3 true WO1991015498A3 (fr) 1992-06-11

Family

ID=27265029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/000639 WO1991015498A2 (fr) 1990-04-04 1991-04-04 Derives nucleosidiques

Country Status (6)

Country Link
EP (1) EP0523110A1 (fr)
JP (1) JPH05505815A (fr)
AU (1) AU7558491A (fr)
CA (1) CA2079796A1 (fr)
OA (1) OA09677A (fr)
WO (1) WO1991015498A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500610A1 (fr) * 1989-11-06 1992-09-02 Nycomed Imaging As Derives de nucleosides
UA41261C2 (uk) * 1992-06-22 2001-09-17 Елі Ліллі Енд Компані Спосіб одержання збагачених бета-аномером нуклеозидів
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
JPH0692987A (ja) * 1992-09-17 1994-04-05 Tanabe Seiyaku Co Ltd ウリジン誘導体およびその製法
JPH11217396A (ja) * 1998-01-30 1999-08-10 Ajinomoto Co Inc ヌクレオシド誘導体の製造方法
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1567169A4 (fr) 2002-11-04 2009-10-21 Xenoport Inc Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations
CN1693309A (zh) * 2005-04-18 2005-11-09 成都正开生物科技发展有限公司 N4－（取代的氧羰基）－2′，2′－二氟－2′－脱氧胞苷衍生物及其应用
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064132A2 (fr) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Triterpénoïdes synthétiques et bis-énones tricycliques pour une utilisation dans la stimulation de croissance osseuse et cartilagineuse
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CA2869460C (fr) 2012-04-04 2018-05-15 Halozyme, Inc. Polytherapie par un agent anti-hyaluronane et un taxane ciblant une tumeur
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2016078397A1 (fr) * 2014-11-17 2016-05-26 常州方圆制药有限公司 Nouveau type de dérivé de cytidine et application de celui-ci
WO2016078160A1 (fr) * 2014-11-17 2016-05-26 常州方圆制药有限公司 Dérivé de cytidine et application de celui-ci
WO2019222435A1 (fr) 2018-05-16 2019-11-21 Halozyme, Inc. Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3651045A (en) * 1968-10-21 1972-03-21 Parke Davis & Co 9-(beta-d-arabinofuranosyl)adenine esters and methods for their production
EP0042596A1 (fr) * 1980-06-23 1981-12-30 The Regents Of The University Of Minnesota Dérivés d'adénosine, leur préparation et compositions pharmaceutiques les contenant
EP0056265A2 (fr) * 1981-01-09 1982-07-21 Dr. Thilo & Co. GmbH Pyrimidinenucléosides estérifiés en position 5' ayant une activité antivirale, méthode pour leur préparation et les médicaments les contenant
EP0104857A1 (fr) * 1982-09-28 1984-04-04 Beecham Group Plc Dérivés de la déoxyuridine, leurs méthodes de préparation et leur emploi en médecine
US4495180A (en) * 1982-06-21 1985-01-22 Merck & Co., Inc. Prodrugs of Ara-A an antiviral agent
EP0151189A1 (fr) * 1983-07-20 1985-08-14 Teijin Limited Agent antineoplastique
EP0217580A2 (fr) * 1985-09-17 1987-04-08 The Wellcome Foundation Limited Nucléosides thérapeutiques
EP0219829A2 (fr) * 1985-10-18 1987-04-29 Sloan-Kettering Institute For Cancer Research Nucléosides 2-fluoro-arabinofuranosyl purine
EP0260852A2 (fr) * 1986-09-08 1988-03-23 The Wellcome Foundation Limited Analogues aux nucléosides
WO1988007532A1 (fr) * 1987-03-24 1988-10-06 Nycomed A.S. Derives d'oxyde de 2',3' didesoxyribofuranne
EP0329348A2 (fr) * 1988-02-16 1989-08-23 Eli Lilly And Company Nucléosides-2',3'-didéoxy-2',2'-difluoro
EP0340778A2 (fr) * 1988-05-06 1989-11-08 Bristol-Myers Squibb Company Prodrogues de 2',3'-didéshydro-2',3'-didésoxynucléosides
EP0341704A2 (fr) * 1988-05-12 1989-11-15 F. Hoffmann-La Roche Ag Procédé pour la préparation de 2',3'-didéoxycytidines
EP0346108A2 (fr) * 1988-06-09 1989-12-13 The Wellcome Foundation Limited Nucléosides anti-infectieux
EP0355031A2 (fr) * 1988-08-17 1990-02-21 MATTHES, Eckart, Dr. Nucléosides pyrimidiniques substitués, leur procédé de préparation et médicaments les contenant
EP0362967A1 (fr) * 1988-10-05 1990-04-11 Nycomed Imaging As Dérivés de nucléosides
EP0366171A1 (fr) * 1988-10-05 1990-05-02 Nycomed As Dérivés de nucléosides
EP0417999A1 (fr) * 1989-09-11 1991-03-20 The Wellcome Foundation Limited Composés antiviraux

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3651045A (en) * 1968-10-21 1972-03-21 Parke Davis & Co 9-(beta-d-arabinofuranosyl)adenine esters and methods for their production
EP0042596A1 (fr) * 1980-06-23 1981-12-30 The Regents Of The University Of Minnesota Dérivés d'adénosine, leur préparation et compositions pharmaceutiques les contenant
EP0056265A2 (fr) * 1981-01-09 1982-07-21 Dr. Thilo & Co. GmbH Pyrimidinenucléosides estérifiés en position 5' ayant une activité antivirale, méthode pour leur préparation et les médicaments les contenant
US4495180A (en) * 1982-06-21 1985-01-22 Merck & Co., Inc. Prodrugs of Ara-A an antiviral agent
EP0104857A1 (fr) * 1982-09-28 1984-04-04 Beecham Group Plc Dérivés de la déoxyuridine, leurs méthodes de préparation et leur emploi en médecine
EP0151189A1 (fr) * 1983-07-20 1985-08-14 Teijin Limited Agent antineoplastique
EP0217580A2 (fr) * 1985-09-17 1987-04-08 The Wellcome Foundation Limited Nucléosides thérapeutiques
EP0219829A2 (fr) * 1985-10-18 1987-04-29 Sloan-Kettering Institute For Cancer Research Nucléosides 2-fluoro-arabinofuranosyl purine
EP0260852A2 (fr) * 1986-09-08 1988-03-23 The Wellcome Foundation Limited Analogues aux nucléosides
WO1988007532A1 (fr) * 1987-03-24 1988-10-06 Nycomed A.S. Derives d'oxyde de 2',3' didesoxyribofuranne
EP0329348A2 (fr) * 1988-02-16 1989-08-23 Eli Lilly And Company Nucléosides-2',3'-didéoxy-2',2'-difluoro
EP0340778A2 (fr) * 1988-05-06 1989-11-08 Bristol-Myers Squibb Company Prodrogues de 2',3'-didéshydro-2',3'-didésoxynucléosides
EP0341704A2 (fr) * 1988-05-12 1989-11-15 F. Hoffmann-La Roche Ag Procédé pour la préparation de 2',3'-didéoxycytidines
EP0346108A2 (fr) * 1988-06-09 1989-12-13 The Wellcome Foundation Limited Nucléosides anti-infectieux
EP0355031A2 (fr) * 1988-08-17 1990-02-21 MATTHES, Eckart, Dr. Nucléosides pyrimidiniques substitués, leur procédé de préparation et médicaments les contenant
EP0362967A1 (fr) * 1988-10-05 1990-04-11 Nycomed Imaging As Dérivés de nucléosides
EP0366171A1 (fr) * 1988-10-05 1990-05-02 Nycomed As Dérivés de nucléosides
EP0417999A1 (fr) * 1989-09-11 1991-03-20 The Wellcome Foundation Limited Composés antiviraux

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
USRE45325E1 (en) 2008-04-18 2015-01-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives

Also Published As

Publication number Publication date
WO1991015498A2 (fr) 1991-10-17
AU7558491A (en) 1991-10-30
OA09677A (en) 1993-05-15
CA2079796A1 (fr) 1991-10-05
JPH05505815A (ja) 1993-08-26
EP0523110A1 (fr) 1993-01-20

Similar Documents

Publication Publication Date Title
WO1991015498A3 (fr) Derives nucleosidiques
BG100916A (en) Process for the diastereoselective synthesis of nucleoside analogues
CA2297294A1 (fr) Derives de phosphonomethoxymethylpurine/pyrimidine
EP1069111A4 (fr) Derives d'indole exer ant une activite antivirale
IL88755A0 (en) Purinyl and pyrimidinyl cyclobutane derivatives and pharmaceutical and veterinary compositions containing the same
AU1489388A (en) 2',3' dideoxyribofuranoxide derivatives
BR0011521B1 (pt) Compostos nucleósidos de purina de 4 -c-etinila
AU5831590A (en) 2-halo-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine nucleoside derivatives
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
EP0502690A3 (en) Cyclopropane derivative
AU4333889A (en) Nucleoside derivatives
EP0770621A4 (fr) 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
AU4425589A (en) Nucleoside derivatives
AU7653300A (en) Carbocyclic nucleosides and process for obtaining such
EP0155164A3 (en) Novel cyanoimidazole nucleoside derivatives
HUT54153A (en) Process for producing purinyl- and pyrimidinyltetrahydrofuran derivatives and pharmaceutical compositions comprising same
CA2188306A1 (fr) Methode pour la synthese diastereoselective d'analogues de nucleosides
MX9604880A (es) Procedimiento para la sintesis diasteroselectiva de analogos de nucleosido.
JPS6426594A (en) Nucleotides and antitumor agent
GB2232669A (en) Novel cyclobutane derivative and process for producing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PAT.BUL.24/91,UNDER PUBLISHED REPLACE "A1" BY "A2"

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2079796

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991906957

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991906957

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991906957

Country of ref document: EP